VivoSeq
Other

Premalignant Lesion

0

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Premalignant Lesion is an early-stage landscape with 0 programs across 2 companies. The most active players are Skyline Biosciences, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

63/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Skyline Biosciences

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Completed5 · 42%
Terminated2 · 17%
Unknown status2 · 17%
Active, not recruiting1 · 8%
Recruiting1 · 8%
Withdrawn1 · 8%

Clinical Trials

Trial Activity

12 trials

Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06561087·45 enrolled
Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05327270·18 enrolled
A Randomized Study of Sulindac in Oral Premalignant Lesions
Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT00299195·63 enrolled
Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck
Completed·EEmory University·Phase 1·NCT01116336·25 enrolled
Chemoprevention of Oral Premalignant Lesions
Completed·Pfizer logoPfizer·Phase 2·NCT00036283·42 enrolled
Treatment of Oral Premalignant Lesions With 5-ALA PDT
Completed·UUniversity of Arkansas·Phase 1/2·NCT00571974·29 enrolled
A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions.
Completed·PPhotocure·Phase 1/2·NCT00369018·96 enrolled
Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions
Terminated·TThomas Jefferson University·Phase 1·NCT05536037·4 enrolled
Pioglitazone for Oral Premalignant Lesions
Terminated·National Cancer Institute (NCI)·Phase 2·NCT00951379·52 enrolled
This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions
Withdrawn·SSkyline Biosciences·Phase 1·NCT03939364
Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization
Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT04065737·29 enrolled
Jianpi Huoxue Recipe in Treating Gastric Premalignant Lesion
Unknown status·XXiyuan Hospital of China Academy of Chinese Medical Sciences·Phase 1/2·NCT03823248·480 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)